TearScience

TearScience

TearScience is an American company founded in 2005 that develops, manufactures and markets ophthalmic medical devices aiding in the identification and treatment of Meibomian gland Dysfunction, also known as Dry eye disease. that affect as many as 25 million Americans,. The company’s Lipiflow System was FDA cleared in June 2011 for treating meibomian gland dysfunction and is currently installed in over 250 locations across the globe. Wikipedia

TearScience

TearScience is an American company founded in 2005 that develops, manufactures and markets ophthalmic medical devices aiding in the identification and treatment of Meibomian gland Dysfunction, also known as Dry eye disease. that affect as many as 25 million Americans,. The company’s Lipiflow System was FDA cleared in June 2011 for treating meibomian gland dysfunction and is currently installed in over 250 locations across the globe. Wikipedia

  • Dec 25 at 2:02 PM
    It's been a great year for us, from joining the J&J Vision family to advancing the understanding of MGD. Thank you to all of our customers and partners. Happy holidays.
  • Dec 22 at 5:23 PM
    86% of dry eye patients are affected by MGD. Take advantage of our year-end specials!
  • Dec 15 at 2:56 PM
    Over 340 million people worldwide suffer from dry eye. Meibomian gland dysfunction is the leading cause of dry eye.
  • Dec 8 at 6:14 PM
    Meibomian gland dysfunction (MGD) is the leading cause of dry eye. It affects approximately 86% of all dry eye patients.

Dec 25, 2:02 PM

It's been a great year for us, from joining the J&J Vision family to advancing the understanding of MGD. Thank you to all of our customers and partners. Happy holidays.

Dec 22, 5:23 PM

86% of dry eye patients are affected by MGD. Take advantage of our year-end specials!

Dec 15, 2:56 PM

Over 340 million people worldwide suffer from dry eye. Meibomian gland dysfunction is the leading cause of dry eye.

Dec 8, 6:14 PM

Meibomian gland dysfunction (MGD) is the leading cause of dry eye. It affects approximately 86% of all dry eye patients.